Industry Today Logo

Published Fri, Dec 7th 2018

Interleukin 1 (IL1) - Pipeline Review, Competitive Landscape & Overview by key players Opsona Therapeutics, Peptinov SAS, R Pharm, Regeneron Pharmaceuticals

A new independent 97 page research with title 'Interleukin 1 (IL1) - Pipeline Review, H2 2018' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes important players/vendors such as Apexigen Inc, Link Health Group, Moderna Therapeutics Inc, Novartis AG etc. With n-number of tables and figures examining the Interleukin 1 (IL1) - Pipeline Review, H2 2018, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022

Posted via Industry Today. Follow us on Twitter @IndustryToday


Request a sample report @ https://www.htfmarketreport.com/sample-report/1452057-interleukin-4
Summary
Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.

Interleukin 1 (IL1) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Cardiovascular, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Genetic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Hematological Disorders which include indications Gouty Arthritis (Gout), Inflammation, Non-Small Cell Lung Cancer, Acne Vulgaris, Atopic Dermatitis (Atopic Eczema), Behcet Disease, Type 2 Diabetes, Arterial Thrombosis, Atherosclerosis, Autoimmune Disorders, Bullous Pemphigoid, Cancer Anorexia-Cachexia Syndrome, Cardiovascular Risk Factors, Cholangitis, Colorectal Cancer, Epidermolysis Bullosa, Esophageal Cancer, Fallopian Tube Cancer, Familial Mediterranean Fever, Hearing Disorders, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Kidney Fibrosis, Limited/Distal Colitis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pain, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Restenosis, Rheumatoid Arthritis, Rhinitis, Sarcoidosis, Sickle Cell Disease, Skin Ulcers and Squamous Non-Small Cell Lung Cancer.
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/1452057-interleukin-4

The latest report Interleukin 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Companies Mentioned in the Report
Apexigen Inc, Link Health Group, Moderna Therapeutics Inc, Novartis AG, Omnitura Therapeutics Inc, Opsona Therapeutics Ltd, Peptinov SAS, R Pharm, Regeneron Pharmaceuticals Inc, Spherium Biomed SL, Swedish Orphan Biovitrum AB, XBiotech Inc

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
- The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics
Place a Purchase Order for this Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=1452057

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interleukin 1 (IL1) - Overview
Interleukin 1 (IL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 (IL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
....Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1452057-interleukin-4

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

 

Contact information

Craig Francis
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
New Jersey
08837
+1 (206) 317 1218
https://www.htfmarketreport.com/

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Visit www.industrytoday.co.uk to publish and distribute news from your Industry. Optimised press releases appear in Google News. Connect with us via the social networks Twitter, Facebook, LinkedIn, Google+ and Pinterest